TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03832426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg film-coated tablets
Study: NCT02558634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIM Thalamic Deep Brain Stimulation ON

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VIM Thalamic Deep Brain Stimulation OFF
Study: NCT01891669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263507
Description: Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06263507
Description: Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study: NCT01927159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02766868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACE-Flu/Bu/Cy
Description: Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
Study: NCT03564613

Intervention type: DRUG
Intervention: DTG
Description: Subjects with DTG exposure during any trimester will be included
Study: NCT04078347

Intervention type: PROCEDURE
Intervention: Paravertebral block at T4 and T5 level
Description: Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.

Intervention type: PROCEDURE
Intervention: Paravertebral block at T4 and T5 level
Description: Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
Study: NCT02650089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Low intensity
Description: The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise High intensity
Description: The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
Study: NCT00657644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
Study: NCT00773513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa will be administered as per approved label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa will be administered as per approved label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered as per approved label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa will be administered as per approved label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Beta
Description: Epoetin beta will be administered as per approved label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methoxy polyethylene glycol-epoetin beta
Description: Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
Study: NCT04104737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spire Medical Health Tag
Description: Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References.
Study: NCT03796065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FSI-R Treatment
Description: The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
Study: NCT00346125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: 9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1
Study: NCT03265626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1: Comprehensive preventive intervention
Description: aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
Study: NCT01993238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)
Description: Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-treatment analgesia
Description: Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
Study: NCT02303275

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Change
Description: Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Change
Description: The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
Study: NCT00346125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: 9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: 45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
Study: NCT03225339

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Energy Diet
Description: Low Energy Diet
Study: NCT03651440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar stabilization training
Description: lumbar stabilization training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical Therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control group
Study: NCT03384576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Classical music to be played in the Emergency waiting room

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No music
Description: No music played in emergency waiting room
Study: NCT00346125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: The surgical procedure will be decided by the treating physician and independent of study participation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: The surgical procedure will be decided by the treating physician and independent of study participation
Study: NCT01786837

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Functional Magnetic Stimulation
Description: 20 minute stimulation will be applied 5 days a week for 5 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation
Description: 20 minute stimulation will be applied 5 days a week for 5 weeks
Study: NCT04818866

Intervention type: DIAGNOSTIC_TEST
Intervention: SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
Description: Biomarkers of inflammation
Study: NCT04939337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-SC01
Description: Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
Study: NCT01211158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol
Description: Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol alone
Description: Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
Study: NCT03257800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
Study: NCT01042288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Study: NCT03205163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advate (Low Dose)
Description: Participants received a single IV low dose of Advate 25 IU/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advate (High Dose)
Description: Participants received a single IV high dose of Advate 65 IU/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIVV001 (Low Dose)
Description: Participants received single IV low dose of BIVV001 25 IU/kg.
Study: NCT04882956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection
Description: Aflipercept intravitreal injection
Study: NCT03205163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIVV001 (High Dose)
Description: Participants received single IV high dose of BIVV001 65 IU/kg.
Study: NCT01643967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sunflower oil
Description: The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone Therapy
Description: The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
Study: NCT03099616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
Study: NCT00346125

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fludeoxyglucose F 18
Description: FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
Study: NCT03099616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
Study: NCT03138421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431 HCl
Description: ABX-1431 HCl, capsules, 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03597620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaderm
Description: Metaderm cream and spray will be apply to subjects scalp and body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaderm
Description: Metaderm cream and spray will be apply to subjects scalp and body.
Study: NCT01862913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavioral therapy
Description: The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
Study: NCT01377207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
Study: NCT01862913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
Study: NCT02318342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
Study: NCT02927392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
Study: NCT00782717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension, 0.1% (NEVANAC)
Description: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac ophthalmic suspension vehicle
Description: 1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate ophthalmic suspension (OMNIPRED)
Description: One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension (OMNIPRED)
Description: One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
Study: NCT02446717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493, ABT-530
Description: ABT-493 (tablet) dosed with ABT-530 (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493, ABT-530
Description: ABT-493 (tablet) dosed with ABT-530 (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493, ABT-530
Description: ABT-493 (tablet) dosed with ABT-530 (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT01669317

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 8-ounce glass of cherry juice
Description: You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-ounce glass of cherry juice
Description: You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Cherry Juice
Description: You will be given an 8-ounce glass of artificial cherry juice
Study: NCT01377207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
Study: NCT01669317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Cherry Juice
Description: You will be given an 8-ounce glass of artificial cherry juice